Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

@article{Ribas2015PembrolizumabVI,
  title={Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.},
  author={Antoni Ribas and Igor J. Puzanov and Reinhard Dummer and Dirk Schadendorf and Omid A. Hamid and C. Coghill Robert and Frank Stephen Hodi and Jacob M Schachter and Anna C Pavlick and Karl D. Lewis and Lee Cranmer and Christian U Blank and Steven J. O'Day and Paolo Antonio Ascierto and April K. S. Salama and Kim A Margolin and Anne Lynn S. Chang and Thomas Kurt Eigentler and Tara C. Gangadhar and Matteo Carlino and Sanjiv S. Agarwala and Stergios J. Moschos and Jeffrey A. Sosman and Simone Maria Goldinger and Ronnie Shapira-Frommer and R. Cabez{\'o}n Gonz{\'a}lez and John Munn Kirkwood and Jedd D Wolchok and Alexander Eggermont and Xiaoyun Li and Wei Guo Zhou and Adriane M Zernhelt and Joy Lis and Scot W. Ebbinghaus and Soonmo Peter Kang and Adil I Daud},
  journal={The Lancet. Oncology},
  year={2015},
  volume={16 8},
  pages={
          908-18
        }
}
BACKGROUND Patients with melanoma that progresses on ipilimumab and, if BRAF(V600) mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed the efficacy and safety of two pembrolizumab doses versus investigator-choice chemotherapy in patients with ipilimumab-refractory melanoma. METHODS We carried out a randomised phase 2 trial of patients aged 18 years or older from 73 hospitals, clinics, and academic medical centres in 12 countries who had confirmed… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 435 CITATIONS, ESTIMATED 41% COVERAGE

Immune checkpoint inhibitors: therapeutic advances in melanoma.

  • Annals of translational medicine
  • 2015
VIEW 14 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma

  • Journal of Cancer Research and Clinical Oncology
  • 2018
VIEW 5 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Risk of immune-related colitis with PD-1/PD-L1 inhibitors vs chemotherapy in solid tumors: systems assessment

  • Journal of Cancer
  • 2018
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis

  • Clinical, cosmetic and investigational dermatology
  • 2017
VIEW 6 EXCERPTS
CITES METHODS, BACKGROUND & RESULTS
HIGHLY INFLUENCED

Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors

  • European Journal of Nuclear Medicine and Molecular Imaging
  • 2017
VIEW 4 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2015
2019

CITATION STATISTICS

  • 42 Highly Influenced Citations

  • Averaged 99 Citations per year from 2017 through 2019

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  • The New England journal of medicine
  • 2015
VIEW 1 EXCERPT

CTLA4 blockade broadens the peripheral T-cell receptor repertoire.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2014